Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
Chakrabarti
Suparno
S
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000494:pharmacology; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D015994:Incidence; D008558:Melphalan / Q000494:pharmacology; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000494:pharmacology; D014775:Virus Activation / Q000187:drug effects; D014916:Whole-Body Irradiation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan